Atea Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $351.4M |
| Operating income | -$180.9M | -$192.9M | -$164.2M | -$130.7M | $138.4M |
| Operating expenses | $180.9M | $192.9M | $164.2M | $130.7M | $213.0M |
| Cash from operations | -$132.0M | -$135.5M | -$85.4M | -$121.0M | -$87.0M |
| Capital expenditure | — | — | — | $1.9M | $4,000 |
| Free cash flow | — | — | — | -$122.9M | -$87.0M |
| Share repurchases | $25.5M | $0 | — | — | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $315.2M | $464.7M | $595.0M | $666.7M | $772.9M |
| Total liabilities | $39.8M | $25.8M | $39.8M | $26.1M | $62.8M |
Shares outstanding 80.0M · Free float 79.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.